For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Melanotan II (MT-II) is a synthetic cyclic lactam analog of alpha-melanocyte-stimulating hormone, developed in the late 1980s at the University of Arizona. It is the parent compound from which bremelanotide (PT-141, FDA-approved for HSDD) was derived. MT-II has Phase 1 and small Phase 2 human data demonstrating reliable skin tanning (Dorr et al., 1996) and potent erectogenic effects (Wessells et al., 1998 and 2000). Clinical development was formally abandoned due to the combination of severe nausea side effects and melanoma safety concerns. It is now sold exclusively through unregulated grey markets, a status associated with documented product contamination, dosing inaccuracy, eruptive naevi, and case reports of melanoma.
The complete Melanotan II profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use